DERMA phase III trial of MAGE-A3 antigen-specific cancer immunotherapeutic (ASCI) as adjuvant therapy in patients with MAGE-A3-positive resected stage III melanoma.

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

The Lancet ◽

10.1016/s0140-6736(08)61033-8 ◽

2008 ◽

Vol 372 (9633) ◽

pp. 117-126 ◽

Cited By ~ 456

Author(s):

Alexander MM Eggermont ◽

Stefan Suciu ◽

Mario Santinami ◽

Alessandro Testori ◽

Wim HJ Kruit ◽

...

Keyword(s):

Adjuvant Therapy ◽

Pegylated Interferon ◽

Interferon Alfa ◽

Phase Iii ◽

Stage Iii ◽

Phase Iii Trial ◽

Stage Iii Melanoma ◽

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

Yearbook of Pediatrics ◽

10.1016/s0084-3954(09)79467-9 ◽

2010 ◽

Vol 2010 ◽

pp. 43-45

Author(s):

J.A. Stockman

Keyword(s):

Adjuvant Therapy ◽

Pegylated Interferon ◽

Interferon Alfa ◽

Phase Iii ◽

Stage Iii ◽

Phase Iii Trial ◽

Stage Iii Melanoma ◽

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

Yearbook of Oncology ◽

10.1016/s1040-1741(09)79278-4 ◽

2009 ◽

Vol 2009 ◽

pp. 189-190

Author(s):

M.S. Gordon

Keyword(s):

Adjuvant Therapy ◽

Pegylated Interferon ◽

Interferon Alfa ◽

Phase Iii ◽

Stage Iii ◽

Phase Iii Trial ◽

Stage Iii Melanoma ◽

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

Yearbook of Medicine ◽

10.1016/s0084-3873(09)79559-8 ◽

2009 ◽

Vol 2009 ◽

pp. 213-214

Author(s):

M.S. Gordon

Keyword(s):

Adjuvant Therapy ◽

Pegylated Interferon ◽

Interferon Alfa ◽

Phase Iii ◽

Stage Iii ◽

Phase Iii Trial ◽

Stage Iii Melanoma ◽

MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (ASCI) as adjuvant therapy in resected stage IB/II non-small cell lung cancer (NSCLC): from proof-of-concept to phase III trial (MAGRIT)

Lung Cancer ◽

10.1016/s0169-5002(09)70030-3 ◽

2009 ◽

Vol 63 ◽

pp. S10

Author(s):

T. Eisen ◽

J. Vansteenkiste ◽

M. Zielinski ◽

A. Linder ◽

J. Dahabreh ◽

...

Keyword(s):

Lung Cancer ◽

Adjuvant Therapy ◽

Small Cell ◽

Phase Iii ◽

Proof Of Concept ◽

Small Cell Lung ◽

Phase Iii Trial ◽

Specific Cancer ◽

Resected Stage ◽

Cancer Immunotherapeutic

102PD MAGE-A3 ANTIGEN-SPECIFIC CANCER IMMUNOTHERAPEUTIC (ASCI) AS ADJUVANT THERAPY IN RESECTED STAGE IB/II NON-SMALL CELL LUNG CANCER (NSCLC): FROM PROOF-OF-CONCEPT TO PHASE III TRIAL (MAGRIT)

Lung Cancer ◽

10.1016/s0169-5002(09)70225-9 ◽

2009 ◽

Vol 64 ◽

pp. S45

Author(s):

B. Passlick ◽

J. Vansteenkiste ◽

M. Zielinski ◽

A. Linder ◽

J. Dahabreh ◽

...

Keyword(s):

Lung Cancer ◽

Adjuvant Therapy ◽

Small Cell ◽

Phase Iii ◽

Proof Of Concept ◽

Small Cell Lung ◽

Phase Iii Trial ◽

Specific Cancer ◽

Resected Stage ◽

Cancer Immunotherapeutic

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

Yearbook of Dermatology and Dermatologic Surgery ◽

10.1016/s0093-3619(09)79330-x ◽

2009 ◽

Vol 2009 ◽

pp. 442-443

Author(s):

P.G. Lang,

Keyword(s):

Adjuvant Therapy ◽

Pegylated Interferon ◽

Interferon Alfa ◽

Phase Iii ◽

Stage Iii ◽

Phase Iii Trial ◽

Stage Iii Melanoma ◽

Serum concentrations of pegylated interferon α-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon α-2b in a randomized phase III trial (EORTC 18991)

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-009-1072-z ◽

2009 ◽

Vol 65 (4) ◽

pp. 671-677 ◽

Cited By ~ 18

Author(s):

Alexander M. M. Eggermont ◽

Marna G. Bouwhuis ◽

Wim H. Kruit ◽

Alessandro Testori ◽

Timo ten Hagen ◽

...

Keyword(s):

Pegylated Interferon ◽

Phase Iii ◽

Stage Iii ◽

Interferon Α ◽

Serum Concentrations ◽

Phase Iii Trial ◽

Stage Iii Melanoma ◽

Faculty Opinions recommendation of Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717958780.793464035 ◽

2012 ◽

Author(s):

Mark Faries

Keyword(s):

Adjuvant Therapy ◽

Pegylated Interferon ◽

Interferon Alfa ◽

Phase Iii ◽

Long Term Results ◽

Phase Iii Trial ◽

Stage Iii Melanoma ◽

EORTC 18991 phase III trial: Long-term adjuvant pegylated interferon-α2b (PEG-IFN) versus observation in resected stage III melanoma: Long-term results at 7.6-years follow-up.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.8506b ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 8506b-8506b ◽

Cited By ~ 12

Author(s):

A. M. Eggermont ◽

S. Suciu ◽

M. Santinami ◽

W. Kruit ◽

A. Testori ◽

...

Keyword(s):

Pegylated Interferon ◽

Phase Iii ◽

Stage Iii ◽

Long Term Results ◽

Phase Iii Trial ◽

Stage Iii Melanoma ◽

Resected Stage ◽

Interferon Α2b